No Data
Wan Nianqing: 2024 Annual Results Forecast
Jiangxi Wannianqing Cement (000789.SZ): Expected net income for the fiscal year 2024 to decrease by 92.13%-94.75%.
On January 22, Gelonghui announced that Jiangxi Wannianqing Cement (000789.SZ) released its 2024 annual performance forecast, estimating that the Net income attributable to shareholders of the listed company will be between 12 million yuan and -18 million yuan, a decrease of 94.75% to 92.13% compared to the same period last year; after deducting non-recurring gains and losses, the net income is expected to be a loss of 38 million yuan to -19 million yuan, a decline of 120.90% to 110.45% year-on-year; the EPS is expected to be between 0.0150 yuan/share and 0.0226 yuan/share. In 2024, the Cement Industry will be affected by the growth rates of Real Estate Investment and Infrastructure Investment.
Yue Jiangxi Wannianqing Cement (301111.SZ): Currently, there is no production or sales of Pharmaceuticals for the treatment of monkeypox.
On January 13, Gelonghui reported that Jiangxi Wannianqing Cement (301111.SZ) stated on the investor interaction platform that the company currently does not produce or sell any Pharmaceuticals for the treatment of monkeypox.
Yue Jiangxi Wannianqing (301111.SZ): Sangqi hypoglycemic tablets are proposed to be selected for centralized bulk purchasing.
On January 2, Gelonghui reported that Guangdong Wannianqing Pharmaceutical Co., Ltd. (301111.SZ) recently participated in the centralized procurement work of the National Chinese Patent Medicine Procurement Alliance. According to the "Proposed Selected Results of the Centralized Bulk Procurement of the National Chinese Patent Medicine Procurement Alliance" issued by the Hubei Medical Insurance Service Platform on December 30, 2024, the company's product, Shensi Jiangtang Tablets, is proposed to be selected for this centralized bulk procurement. This proposed selected product, Shensi Jiangtang Tablets, is the company's exclusive formulation and is included in the National Medical Insurance and National Basic Drug List. The sales revenue of the company's Shensi Jiangtang Tablets for the 2023 fiscal year was 0.113 billion yuan, accounting for the company's 202...
Jiangxi Wannianqing Cement (000789.SZ): plans to register and issue corporate bonds not exceeding 2 billion yuan.
Gelonghui reported on December 30 that Jiangxi Wannianqing Cement (000789.SZ) announced that the company will hold the second extraordinary meeting of the tenth Board of Directors and the second extraordinary meeting of the tenth Supervisory Board on December 27, 2024. The meetings approved the proposal regarding the proposed registration and issuance of corporate bonds, to enhance the company's capital security capacity, further broaden financing channels, and optimize the financing structure. The company agrees to apply to the Shenzhen Securities Exchange for public issuance of corporate bonds after being registered with the China Securities Regulatory Commission. The issuance amount of these corporate bonds will not exceed 2 billion yuan (including 2 billion yuan), with a specific issuance scale to be determined.
Jiangxi Wannianqing Cement (000789.SZ): Jiangxi Cement has cumulatively increased its shareholding by 0.87%.
On December 26, Gelonghui announced that Jiangxi Wannianqing Cement (000789.SZ) increased its shareholding through the Exchange trading system by a cumulative 6,905,400 shares from June 25 to December 24, 2024, accounting for 0.87% of the total share capital of Wannianqing. The amount for the increased shares was 32,374,166.00 yuan. After this increase, Jiangxi Wannianqing Cement holds 354,385,404 shares of the company, accounting for 44.44% of the total share capital.
